Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Tumor-Immune Architecture and the Regulation of Antigen-Specific T-Cell Infiltration in Multiple Myeloma and Premalignant Plasma Cell Disorders

Blood (2022) 140 (Supplement 1): 244–245.

https://doi.org/10.1182/blood-2022-169558

Published: 2022

Journal Articles

BRAF Mutations and Inflammatory Gene Expression in Myeloma Cells from Patients with Renal Dysfunction

Theodora Alese, Benjamin G Barwick, Vikas A. Gupta, Nisha Joseph, Craig C. Hofmeister, Mala Shanmugam, Jonathan L. Kaufman, Madhav V Dhodapkar, Sagar Lonial, Ajay K. Nooka, Lawrence H. Boise

Blood (2021) 138 (Supplement 1): 1624.

https://doi.org/10.1182/blood-2021-154092

Published: 2021

Journal Articles

Daratumumab with Pomalidomide and Dexamethasone at First Relapse in Relapsed and/or Refractory Multiple Myeloma (RRMM) Patients

Nisha Joseph, Kathryn T. Maples, Kevin Hall, Vikas A Gupta, Larry H. Boise, Leonard T. Heffner, Madhav V Dhodapkar, Craig C. Hofmeister, Jonathan L. Kaufman, Sagar Lonial, Ajay K. Nooka

Blood (2021) 138 (Supplement 1): 1616.

https://doi.org/10.1182/blood-2021-151161

Published: 2021

Journal Articles

Evaluating Outcomes for Autologous Hematopoietic Cell Transplantation for Diffuse Large B-Cell Lymphoma in the CAR-T Era

Blood (2020) 136 (Supplement 1): 20–21.

https://doi.org/10.1182/blood-2020-142110

Published: 2020

Journal Articles

Role of clonoSEQ ® , a Next-Generation Sequencing (NGS) Assay and PET/CT As a Measure of Minimal Residual Disease Negativity Among Patients with Multiple Myeloma

Ajay Nooka, MDMPH, Kyle Bradley, MD MS, Nisha Joseph, MD, Craig C Hofmeister, MDMPH, Madhav V. Dhodapkar, MD, Larry H. Boise, PhD, Sagar Lonial, MD FACP, Shiyong Li, MD PhD, Jonathan L. Kaufman, MD

Blood (2020) 136 (Supplement 1): 50–51.

https://doi.org/10.1182/blood-2020-143093

Published: 2020

Journal Articles

Real World Experience and Patient Satisfaction Surrounding the Implementation of Daratumumab and Hyaluronidase-Fihj in a Large, Academic Medical Center

Kathryn T. Maples, PharmD, Erich Brechtelsbauer, PharmD, Julia Pendexter, PharmD, Jonathan L. Kaufman, MD, Nisha Joseph, MD, Leonard Heffner, MD, Craig C Hofmeister, MDMPH, Madhav V. Dhodapkar, MD, Sagar Lonial, MD FACP, Ajay Nooka, MDMPH

Blood (2020) 136 (Supplement 1): 9.

https://doi.org/10.1182/blood-2020-142995

Published: 2020

Journal Articles

Outcomes of Elderly Patients Undergoing Allogeneic Transplantation for Acute Myeloid Leukemia with Fludarabine/Melphalan or Fludarabine/TBI Conditioning Regimen

Ashley C Woods, MD, Nisha Joseph, MD, Manali Rupji, MS, Yuan Liu, PhD, Amelia Langston, MD, Edmund K. Waller, PhDMD

Blood (2019) 134 (Supplement_1): 3331.

https://doi.org/10.1182/blood-2019-130581

Published: 2019

Journal Articles

Efficacy of Induction Thearapy with Lenalidomide, Bortezomib, and Dexamethasone (RVD) in 1000 Newly Diagnosed Multiple Myeloma (MM) Patients

Nisha Joseph, MD, Vikas A. Gupta, MD PhD, Craig C Hofmeister, MD MPH, Charise Gleason, ANP, Leonard Heffner, MD, Lawrence H. Boise, PhD, Jonathan L Kaufman, MD, Madhav V Dhodapkar, MD, Sagar Lonial, MD, Ajay K Nooka, MD MPH

Blood (2018) 132 (Supplement 1): 3294.

https://doi.org/10.1182/blood-2018-99-119895

Published: 2018

Journal Articles

Impact of Early Progression on Long Term Outcomes Among Myeloma Patients Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD) Induction Therapy

Ajay K Nooka, MDMPH, Jonathan L Kaufman, MD, Charise Gleason, ANP, Nisha Joseph, MD, Craig C Hofmeister, MD MPH, Lawrence H. Boise, PhD, Leonard Heffner, MD, Madhav V Dhodapkar, MD, Sagar Lonial, MD

Blood (2018) 132 (Supplement 1): 3302.

https://doi.org/10.1182/blood-2018-99-120314

Published: 2018

Journal Articles

Safety and Efficacy of Evomela™ in Myeloma Autotransplants

Kimberly Amelsberg, Nisha Joseph, MD, Amelia Langston, MD, Jonathan L Kaufman, MD, Craig C Hofmeister, MD MPH, Edmund K. Waller, MD, Michael Graiser, PhD, Robin Larocco, Leonard Heffner, MD, Madhav V Dhodapkar, MD, Sagar Lonial, MD, Ajay K Nooka, MD MPH

Blood (2018) 132 (Supplement 1): 3446.

https://doi.org/10.1182/blood-2018-99-119730

Published: 2018

Journal Articles

Outcomes and Clinical Features of Patients with 1q+ Multiple Myeloma Treated with Lenalidomide, Bortezomib, and Dexamethasone

Timothy M. Schmidt, MD, Nisha Joseph, MD, Levani Odikadze, MD MPH, Leonard Heffner, MD, Craig C Hofmeister, MD MPH, Madhav V Dhodapkar, MD, Vikas A. Gupta, MD PhD, Lawrence H. Boise, PhD, David L. Jaye, MD, Sagar Lonial, MD, Ajay K Nooka, MD MPH, Jonathan L Kaufman, MD

Blood (2018) 132 (Supplement 1): 3241.

https://doi.org/10.1182/blood-2018-99-112216

Published: 2018

Journal Articles

Differences in Presentation and Survival Outcomes for African American Patients with Newly Diagnosed Multiple Myeloma

Blood (2018) 132 (Supplement 1): 5647.

https://doi.org/10.1182/blood-2018-99-119948

Published: 2018

Journal Articles

Outcomes of Myeloma Patients with t(11;14) Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD) Induction Therapy

Jonathan L Kaufman, MD, Nisha Joseph, MD, Vikas A. Gupta, MD PhD, Charise Gleason, ANP, Craig C Hofmeister, MD MPH, Leonard Heffner, MD, Madhav V Dhodapkar, MD, Sagar Lonial, MD, Lawrence H. Boise, PhD, Ajay K Nooka, MD MPH

Blood (2018) 132 (Supplement 1): 3282.

https://doi.org/10.1182/blood-2018-99-119051

Published: 2018

Journal Articles

Outcomes of Myeloma Patients with Deletion 1p Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD) Therapy

Levani Odikadze, MD MPH, Nisha Joseph, MD, Timothy M. Schmidt, MD, Leonard Heffner, MD, Craig C Hofmeister, MD MPH, Madhav V Dhodapkar, MD, Vikas A. Gupta, MD PhD, Lawrence H. Boise, PhD, David L. Jaye, MD, Sagar Lonial, MD, Ajay K Nooka, MD MPH, Jonathan L Kaufman, MD

Blood (2018) 132 (Supplement 1): 1884.

https://doi.org/10.1182/blood-2018-99-114368

Published: 2018

Journal Articles

Lenalidomide, Bortezomib, and Dexamethasone (RVD) As Induction Therapy in Newly Diagnosed Multiple Myeloma (MM)

Nisha Joseph, MD, Dhwani Almaula, MBBS, Charise Gleason, ANP, Leonard Heffner, MD, Lawrence H. Boise, PhD, Jonathan L. Kaufman, MD, Sagar Lonial, MD, Ajay Nooka, MDMPH

Blood (2017) 130 (Supplement 1): 3139.

https://doi.org/10.1182/blood.V130.Suppl_1.3139.3139

Published: 2017

Journal Articles

Clinical Efficacy of Daratumumab, Pomalidomide and Dexamethasone in Relapsed, Refractory Myeloma Patients: Utility of Retreatment with Daratumumab Among Refractory Patients

Ajay K Nooka, MD MPH, Nisha Joseph, MD, Larry H Boise, PhD, Charise Gleason, MSN, ANP-BC, AOCNP, Jonathan L. Kaufman, MD, Sagar Lonial, MD FACP

Blood (2016) 128 (22): 492.

https://doi.org/10.1182/blood.V128.22.492.492

Published: 2016

Journal Articles

Patterns of Relapse Among Myeloma Patients Post-Autologous Stem Cell Transplant

Prashanth Kumar, Nisha Joseph, MD, Dhwani Almaula, MPH, Lawrence H Boise, PhD, Jonathan L. Kaufman, MD, Charise Gleason, MSN, ANP-BC, AOCNP, Sagar Lonial, MD FACP, Ajay K Nooka, MD MPH

Blood (2016) 128 (22): 4524.

https://doi.org/10.1182/blood.V128.22.4524.4524

Published: 2016

NARROW

Tumor-Immune Architecture and the Regulation of Antigen-Specific T-Cell Infiltration in Multiple Myeloma and Premalignant Plasma Cell Disorders

BRAF Mutations and Inflammatory Gene Expression in Myeloma Cells from Patients with Renal Dysfunction

Daratumumab with Pomalidomide and Dexamethasone at First Relapse in Relapsed and/or Refractory Multiple Myeloma (RRMM) Patients

Evaluating Outcomes for Autologous Hematopoietic Cell Transplantation for Diffuse Large B-Cell Lymphoma in the CAR-T Era

Role of clonoSEQ ® , a Next-Generation Sequencing (NGS) Assay and PET/CT As a Measure of Minimal Residual Disease Negativity Among Patients with Multiple Myeloma

Real World Experience and Patient Satisfaction Surrounding the Implementation of Daratumumab and Hyaluronidase-Fihj in a Large, Academic Medical Center

Outcomes of Elderly Patients Undergoing Allogeneic Transplantation for Acute Myeloid Leukemia with Fludarabine/Melphalan or Fludarabine/TBI Conditioning Regimen

Efficacy of Induction Thearapy with Lenalidomide, Bortezomib, and Dexamethasone (RVD) in 1000 Newly Diagnosed Multiple Myeloma (MM) Patients

Impact of Early Progression on Long Term Outcomes Among Myeloma Patients Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD) Induction Therapy

Safety and Efficacy of Evomela™ in Myeloma Autotransplants

Outcomes and Clinical Features of Patients with 1q+ Multiple Myeloma Treated with Lenalidomide, Bortezomib, and Dexamethasone

Differences in Presentation and Survival Outcomes for African American Patients with Newly Diagnosed Multiple Myeloma

Outcomes of Myeloma Patients with t(11;14) Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD) Induction Therapy

Outcomes of Myeloma Patients with Deletion 1p Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD) Therapy

Lenalidomide, Bortezomib, and Dexamethasone (RVD) As Induction Therapy in Newly Diagnosed Multiple Myeloma (MM)

Clinical Efficacy of Daratumumab, Pomalidomide and Dexamethasone in Relapsed, Refractory Myeloma Patients: Utility of Retreatment with Daratumumab Among Refractory Patients

Patterns of Relapse Among Myeloma Patients Post-Autologous Stem Cell Transplant

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only